Skip to main content
. Author manuscript; available in PMC: 2019 Jan 28.
Published in final edited form as: Arch Toxicol. 2018 Apr 3;92(6):1969–1981. doi: 10.1007/s00204-018-2196-x

Fig. 1.

Fig. 1

Metabolism of dronedarone in individual CYP-overexpressing HepG2 cells. UPLC-QDa mass spectrometry chromatograms for dronedarone and its metabolite N-desbutyl-dronedarone in extract from HepG2-empty vector control (EV) and HepG2-CYP3A4 over-expressing cells treated with 6 μM dronedarone for 24 h. b, c Fourteen CYP-overexpressing HepG2 cell lines were exposed to 6 μM dronedarone for 24 h. The total amount of dronedarone (b) and its metabolite N-desbutyl-dronedarone (c) in cell lysate and culture media were quantified with LC–MS. The results shown are relative values normalized to EV control. Data represent mean ± SD from three independent experiments. *p < 0.05 compared with EV control